David Hallas Acquires 29,897 Shares of ECO Animal Health Group plc (LON:EAH) Stock

ECO Animal Health Group plc (LON:EAH) insider David Hallas acquired 29,897 shares of the company’s stock in a transaction on Tuesday, July 15th. The stock was purchased at an average cost of GBX 67 ($0.90) per share, for a total transaction of £20,030.99 ($26,880.02).

David Hallas also recently made the following trade(s):

• On Friday, April 25th, David Hallas acquired 29,962 shares of ECO Animal Health Group stock. The stock was purchased at an average cost of GBX 67 ($0.90) per share, for a total transaction of £20,074.54 ($26,938.46).

ECO Animal Health Group Trading Up 11.3%

LON EAH opened at GBX 76.80 ($1.03) on Thursday. The company has a debt-to-equity ratio of 4.81, a current ratio of 2.96 and a quick ratio of 2.14. The firm’s fifty day moving average price is GBX 61.77 and its 200 day moving average price is GBX 60.76. The company has a market capitalization of £52.04 million, a price-to-earnings ratio of 49.65 and a beta of -0.05. ECO Animal Health Group plc has a 12 month low of GBX 50 ($0.67) and a 12 month high of GBX 122.25 ($1.64).

ECO Animal Health Group (LON:EAH) last issued its quarterly earnings data on Monday, July 14th. The company reported GBX 2.49 ($0.03) earnings per share (EPS) for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Analyst Upgrades and Downgrades

Separately, Shore Capital reaffirmed a “buy” rating and issued a GBX 150 ($2.01) target price on shares of ECO Animal Health Group in a research report on Monday.

ECO Animal Health Group Company Profile

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.